BMO Capital Reiterates Outperform Rating on Amgen (AMGN)

May 20, 2024 5:20 AM EDT Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $355.00 price target on Amgen (NASDAQ: AMGN)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login